


A Tick Molecule to Rescue Lives after Intracerebral Hemorrhage

S. DEMOULIN, V. PIREAUX, M. DECHAMPS, H. WARRINNIER,



Following an intracerebral hemorrhage (ICH), brain bleeding initiates inflammation and blood clots, which frequently exacerbate the injury, resulting in poor outcomes.

BIOXODES is investigating a new treatment option named **BIOX-101** (Ir-CPI), which focuses on addressing this inflammation and undesirable blood clots, potentially enhancing the recovery of patients.



BIOX-101

- A strong anticlotting effect with no increased bleeding risk!
- Anti-inflammatory effect (neutrophil inhibition).
- Specifically designed for ICH: fits the need during the first 72h after disease onset.



Potential impact

- Each year, > 3 million people worldwide experience ICH, resulting in 2.8 million deaths.
- There is no specific treatment available!



Key preclinical findings (ICH mouse model)

- BIOX-101 does not worsen lesion or bleeding after ICH as compared to placebo.
- BIOX-101 reduces harmful inflammation & protects neuronal cells from damage.
- BIOX-101 improves functional recovery as compared to placebo.

BIOX-101 could be a **game-changer** in hemorrhagic stroke treatment. BIOXODES is currently running a **Phase 2a trial in Belgium** with ICH patients to test BIOX-101, offering a **breakthrough hope** for millions of patients around the world.







